focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 23.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.174%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Harmony Energy plans raise; Kavango sets drill target

Wed, 28th Sep 2022 22:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Harmony Energy Income Trust PLC - London-based investment company focused on energy projects - Proposes capital raising through issue of new C shares, which will be used to fund its pipeline of 2-hour duration battery energy storage systems. Notes it has exclusivity via a right of first refusal over 687.5 megawatts of pipeline of additional 2-hour duration BESS projects which are under the control of Harmony Energy Ltd. Will issue new C shares at 100 pence, with the maximum to be raised at GBP130 million. Also notes it is targeting 8p annual dividend from 2023 onwards.

Chair Norman Crighton adds: "Whilst recognising the current challenging economic and market backdrop, we believe it to be beneficial for the company, with our shareholders' support, to take advantage of its exclusive rights over Harmony Energy's pipeline as envisaged at IPO and continue to build on the positive momentum."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Notes University of Birmingham study in head and neck squamous cell carcinoma which uses company's Parsortix. The study shows HNSCC sees epithelial-mesenchymal transition status of circulating tumour cells. "EMT is clinically significant due to its role in tumour progression and invasion, the development of metastasis, metabolic reprogramming, immune evasion, and resistance of cancer cells to therapy," it adds. Chief Executive Andrew Newland "pleased" Parsortix system as a tool for HNSCC EMT classification.

----------

Engage XR Holdings PLC - Waterford City, Ireland-based virtual communications solutions - Notes consumer electronics firm Lenovo launches virtual reality headset, which will see Engage build its own 'Lenovo Metaverse'. "Engage XR will help build and offer a Lenovo presence within the Metaverse using Engage Link. Engage Link is Engage's enterprise-focused metaverse set to launch later this year. Lenovo is one of the five confirmed launch partners for Engage Link," it explains.

----------

Kavango Resources PLC - London-based mineral explorer focused on Botswana - Finalises drill strategy for four of its prospecting licences in the Kalahari Copper Belt. Finds 13 target areas across licences. Chief Executive Ben Turney says: "Through our flexible proposed drill programme, we have a total of 188 viable drill locations over 13 priority areas, each of which we believe gives us the chance of encountering copper mineralisation. In total, our exploration drilling could total as much as 37,600 metres, which emphasises the scale of Kavango's opportunity. Our ground could host multiple deposits, which is why we have been as thorough as we have in our approach."

----------

Atlantic Lithium Ltd - lithium asset developer and producer focused in West Africa - Partner at Ewoyaa project in Ghana, Piedmont Lithium, completes pre-feasibility study for the project. Says the study shows 255,000 tonnes per year of 6% lithium spodumene concentrate over 12 and a half year mine life with ore reserves of 18.9 million tonnes at 1.24% lithium oxide.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.